Iron chelation therapy in myelodysplastic syndromes: evidence-based rationale and comparison of guidelines
Iron overload has been identified as important factor influencing the clinical course of patients with myelodysplastic syndromes. Chelating agents are available for the treatment of iron overload. Given the lack of data from prospective studies on the effects of iron chelation on the outcome of MDS patients, several guidelines for the use of chelators have been published. This article compares these guidelines and reviews the evidence for the recommendations.